Sumitomo Dainippon Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd.

Taro Kato

Hidefumi Yoshinaga

Masakazu Hashimoto

Hidetaka Nagata

Satoko Shimizu

Yoshiharu Uruno

The purpose of the present invention is to provide: a therapeutic agent or a recurrence preventive agent for serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease; and a method for treating the aforesaid symptoms or preventing the recurrence of the same. A compound represented by formula (1) [wherein each symbol is as defined in the description] or a pharmaceutically acceptable salt thereof can exhibit an effect of treating serotonergic system- or dopaminergic system-related diseases, in particular, mental dysfunction symptoms and other non-motor symptoms of Parkinson's disease and/or an effect of preventing the recurrence of the same. 

Therapeutic agent for non-motor symptoms associated with Parkinson's disease

The present invention provides a cyclic aminomethyl pyrimidine derivative and a pharmaceutically acceptable salt thereof with high selectivity for dopamine Dreceptors, which are useful for treating a disease such as attention deficit hyperactivity disorder. Specifically, a compound of formula (1) or a pharmaceutically acceptable salt thereof is provided, wherein n and m are independently 1 or 2; Ris Calkyl group, Ccycloalkyl group, or amino group; Ris hydrogen atom, Calkyl group or the like, provided that when Ris amino group, then Ris hydrogen atom; Rand Rare independently hydrogen atom, or Calkyl group; Rand Rare independently hydrogen atom, fluorine atom or the like; ring Q is an optionally-substituted pyridyl group or an optionally-substituted isoquinolyl group; and the bond having a dashed line is a single or double bond. 

Cyclic aminomethyl pyrimidine derivative

Growing community of inventors

Osaka, Japan

Taro Kato